Drug Profile
FG 3622
Alternative Names: FG-3622Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator F2G
- Class Antifungals; Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Mycoses in United Kingdom (PO, Suspension)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mycoses in United Kingdom (IV)
- 06 Jul 2009 Phase-I clinical trials in Mycoses in United Kingdom (PO)